Omata Masao, Cheng Ann-Lii, Kokudo Norihiro, Kudo Masatoshi, Lee Jeong Min, Jia Jidong, Tateishi Ryosuke, Han Kwang-Hyub, Chawla Yoghesh K, Shiina Shuichiro, Jafri Wasim, Payawal Diana Alcantara, Ohki Takamasa, Ogasawara Sadahisa, Chen Pei-Jer, Lesmana Cosmas Rinaldi A, Lesmana Laurentius A, Gani Rino A, Obi Shuntaro, Dokmeci A Kadir, Sarin Shiv Kumar
Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu-city, Yamanashi, Japan.
The University of Tokyo, Tokyo, Japan.
Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15.
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.
肝细胞癌（HCC）的分布存在很大的地域差异，全球大多数病例都出现在亚太地区，在该地区，HCC是主要的公共卫生问题之一。自亚太肝脏研究协会（APASL）第25届年会在东京召开的“迈向修订亚太肝脏研究协会（APASL）HCC指南”会议以来，APASL发布的最新HCC治疗指南一直受到讨论。这份最新指南推荐对HCC进行循证管理，并被认为适用于医疗环境多样的亚太地区广泛使用。
